Hepatology International

, Volume 12, Issue 1, pp 6–16 | Cite as

Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis

  • Abdul M. Oseini
  • Banumathi K. Cole
  • Danny Issa
  • Ryan E. Feaver
  • Arun J. Sanyal
Review Article
  • 368 Downloads

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world, affecting about 1/3 of the US general population and remaining as a significant cause of morbidity and mortality. The hallmark of the disease is the excessive accumulation of fat within the liver cells (hepatocytes), which eventually paves the way to cellular stress, injury and apoptosis. NAFLD is strongly associated with components of the metabolic syndrome and is fast emerging as a leading cause of liver transplant in the USA. Based on clinico-pathologic classification, NAFLD may present as isolated lipid collection (steatosis) within the hepatocytes (referred to as non-alcoholic fatty liver; NAFL); or as the more aggressive phenotype (known as non-alcoholic steatohepatitis; NASH). There are currently no regulatory agency- approved medication for NAFLD, despite the enormous work and resources that have gone into the study of this condition. Therefore, there remains a huge unmet need in developing and utilizing pre-clinical models that will recapitulate the disease condition in humans. In line with progress being made in developing appropriate disease models, this review highlights the cutting-edge preclinical in vitro and animal models that try to recapitulate the human disease pathophysiology and/or clinical manifestations.

Keywords

Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic steatohepatitis (NASH) Organotypic liver system Lipitoxic system Diet induced animal model of non-alcoholic fatty liver disease (DIAMOND) Farnesoid X receptor (FXR) 

Notes

Acknowledgement

Support: RO1 DK 105961 (National Institute of Diabetes and Digestive and Kidney Diseases). T32 DK007150/DK/NIDDK NIH HHS/United States [National Institute of Diabetes and Digestive and Kidney Diseases (US)]. R44 DK115301 (SBIR, HemoShear Therapeutics).

Compliance with ethical standards

Conflict of interest

Abdul M. Oseini, MD No conflicts to disclose, Danny Issa, MD No conflicts to disclose, Ryan E. Feaver, PhD Employee of HemoShear, Banumathi K. Cole, PhD Employee of HemoShear. Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect, Exhalenz and Hemoshear. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Jannsen and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Novo Nordisk, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate.

References

  1. 1.
    Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10(11):686–90.  https://doi.org/10.1038/nrgastro.2013.171.CrossRefPubMedGoogle Scholar
  2. 2.
    Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int 2017;37(Suppl 1):97–103.  https://doi.org/10.1111/liv.13302.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141(4):1249–53.  https://doi.org/10.1053/j.gastro.2011.06.061.CrossRefPubMedGoogle Scholar
  4. 4.
    Hirsova P, Gores GJ. Ballooned hepatocytes, undead cells, sonic hedgehog, and vitamin E: therapeutic implications for nonalcoholic steatohepatitis. Hepatology 2015;61(1):15–7.  https://doi.org/10.1002/hep.27279.CrossRefPubMedGoogle Scholar
  5. 5.
    Bedossa P. Histological assessment of NAFLD. Dig Dis Sci 2016;61(5):1348–55.  https://doi.org/10.1007/s10620-016-4062-0.CrossRefPubMedGoogle Scholar
  6. 6.
    Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2017;.  https://doi.org/10.1002/hep.29367.Google Scholar
  7. 7.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84.  https://doi.org/10.1002/hep.28431.CrossRefPubMedGoogle Scholar
  8. 8.
    Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 2016;10(1):63–71.  https://doi.org/10.1586/17474124.2016.1099433.CrossRefPubMedGoogle Scholar
  9. 9.
    Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47–64.  https://doi.org/10.1016/j.jhep.2014.12.012.CrossRefPubMedGoogle Scholar
  10. 10.
    Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13(4):511–31.  https://doi.org/10.1016/j.cld.2009.07.005.CrossRefPubMedGoogle Scholar
  11. 11.
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9(6):524.  https://doi.org/10.1016/j.cgh.2011.03.020.CrossRefPubMedGoogle Scholar
  12. 12.
    European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59(6):1121–40.  https://doi.org/10.1007/s00125-016-3902-y.
  13. 13.
    Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-US Food and Drug Administration Joint Workshop. Hepatology 2015;61(4):1392–405.  https://doi.org/10.1002/hep.27678.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Asgharpour A, Cazanave SC, Pacana T, Seneshaw M, Vincent R, Banini BA, et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 2016;65(3):579–88.  https://doi.org/10.1016/j.jhep.2016.05.005.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, et al. In vitro platforms for evaluating liver toxicity. Exp Biol Med (Maywood) 2014;239(9):1180–91.  https://doi.org/10.1177/1535370214531872.CrossRefGoogle Scholar
  16. 16.
    Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol 2014;32(8):760–72.  https://doi.org/10.1038/nbt.2989.CrossRefPubMedGoogle Scholar
  17. 17.
    Chang SY, Weber EJ, Ness KV, Eaton DL, Kelly EJ. Liver and kidney on chips: microphysiological models to understand transporter function. Clin Pharmacol Ther 2016;100(5):464–78.  https://doi.org/10.1002/cpt.436.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Dash A, Blackman BR, Wamhoff BR. Organotypic systems in drug metabolism and toxicity: challenges and opportunities. Expert Opin Drug Metab Toxicol 2012;8(8):999–1014.  https://doi.org/10.1517/17425255.2012.693161.CrossRefPubMedGoogle Scholar
  19. 19.
    LeCluyse EL, Witek RP, Andersen ME, Powers MJ. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 2012;42(6):501–48.  https://doi.org/10.3109/10408444.2012.682115.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Gao X, Liu Y. A transcriptomic study suggesting human iPSC-derived hepatocytes potentially offer a better in vitro model of hepatotoxicity than most hepatoma cell lines. Cell Biol Toxicol 2017;33(4):407–21.  https://doi.org/10.1007/s10565-017-9383-z.CrossRefPubMedGoogle Scholar
  21. 21.
    Hart SN, Li Y, Nakamoto K, Subileau EA, Steen D, Zhong XB. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos 2010;38(6):988–94.  https://doi.org/10.1124/dmd.109.031831.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rodriguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, et al. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002;32(6):505–20.  https://doi.org/10.1080/00498250210128675.CrossRefPubMedGoogle Scholar
  23. 23.
    Guguen-Guillouzo C, Clement B, Campion JP, Brechot C, Fauchet R, Brissot P, et al. Excretion of HBs and HBe antigens by normal human adult hepatocytes infected in vitro by hepatitis B virus. Presse Med 1983;12(19):1232–3.PubMedGoogle Scholar
  24. 24.
    Krause P, Saghatolislam F, Koenig S, Unthan-Fechner K, Probst I. Maintaining hepatocyte differentiation in vitro through co-culture with hepatic stellate cells. Vitro Cell Dev Biol Anim 2009;45(5–6):205–12.  https://doi.org/10.1007/s11626-008-9166-1.CrossRefGoogle Scholar
  25. 25.
    Takayama G, Taniguchi A, Okano T. Identification of differentially expressed genes in hepatocyte/endothelial cell co-culture system. Tissue Eng 2007;13(1):159–66.  https://doi.org/10.1089/ten.2006.0143.CrossRefPubMedGoogle Scholar
  26. 26.
    Ljssennagger N, Janssen AW, Milona A, Ramos Pittol JM, Hollman DA, Mokry M, et al. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid. J Hepatol 2016;64(5):1158–66.  https://doi.org/10.1016/j.jhep.2016.01.016.CrossRefGoogle Scholar
  27. 27.
    Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009;3(4):445–51.  https://doi.org/10.1586/egh.09.32.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kostrzewski T, Cornforth T, Snow SA, Ouro-Gnao L, Rowe C, Large EM, et al. Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease. World J Gastroenterol 2017;23(2):204–15.  https://doi.org/10.3748/wjg.v23.i2.204.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Gori M, Simonelli MC, Giannitelli SM, Businaro L, Trombetta M, Rainer A. Investigating nonalcoholic fatty liver disease in a liver-on-a-chip microfluidic device. PLoS ONE 2016;11(7):e0159729.  https://doi.org/10.1371/journal.pone.0159729.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 2016;150(5):1147–1159.  https://doi.org/10.1053/j.gastro.2016.01.038.CrossRefPubMedGoogle Scholar
  31. 31.
    Feaver RE, Cole BK, Lawson MJ, Hoang SA, Marukian S, Blackman BR, et al. Development of an in vitro human liver system for interrogating nonalcoholic steatohepatitis. JCI Insight 2016;1(20):e90954.  https://doi.org/10.1172/jci.insight.90954.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002;21(3):219–23.CrossRefPubMedGoogle Scholar
  33. 33.
    Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46(4):1081–90.  https://doi.org/10.1002/hep.21763.CrossRefPubMedGoogle Scholar
  34. 34.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385(9972):956–65.  https://doi.org/10.1016/S0140-6736(14)61933-4.CrossRefPubMedGoogle Scholar
  35. 35.
    Dash A, Figler RA, Blackman BR, Marukian S, Collado MS, Lawson MJ, et al. Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro 2017;39:93–103.  https://doi.org/10.1016/j.tiv.2016.11.014.CrossRefPubMedGoogle Scholar
  36. 36.
    Perla FM, Prelati M, Lavorato M, Visicchio D, Anania C. The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease. Children (Basel) 2017;4(6):46.  https://doi.org/10.3390/children4060046.PubMedCentralGoogle Scholar
  37. 37.
    Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016;65(8):1049–61.  https://doi.org/10.1016/j.metabol.2016.02.014.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol 2016;11:451–96.  https://doi.org/10.1146/annurev-pathol-012615-044224.CrossRefPubMedGoogle Scholar
  39. 39.
    Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295(5):G987–95.  https://doi.org/10.1152/ajpgi.90272.2008.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301(5):G825–34.  https://doi.org/10.1152/ajpgi.00145.2011.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Novik E, Maguire TJ, Chao P, Cheng KC, Yarmush ML. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem Pharmacol 2010;79(7):1036–44.  https://doi.org/10.1016/j.bcp.2009.11.010.CrossRefPubMedGoogle Scholar
  42. 42.
    Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 2013;268(1):1–16.  https://doi.org/10.1016/j.taap.2013.01.012.CrossRefPubMedGoogle Scholar
  43. 43.
    Huh D, Kim HJ, Fraser JP, Shea DE, Khan M, Bahinski A, et al. Microfabrication of human organs-on-chips. Nat Protoc 2013;8(11):2135–57.  https://doi.org/10.1038/nprot.2013.137.CrossRefPubMedGoogle Scholar
  44. 44.
    Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Shun TY, Gough A, et al. A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med (Maywood). 2016;241(1):101–14.  https://doi.org/10.1177/1535370215592121.CrossRefPubMedGoogle Scholar
  45. 45.
    Khetani SR, Bhatia SN. Microscale culture of human liver cells for drug development. Nat biotechnol 2008;26(1):120–6.  https://doi.org/10.1038/nbt1361.CrossRefPubMedGoogle Scholar
  46. 46.
    Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, et al. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol sci 2013;132(1):107–17.  https://doi.org/10.1093/toxsci/kfs326.CrossRefPubMedGoogle Scholar
  47. 47.
    March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N, et al. Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. Nat protoc 2015;10(12):2027–53.  https://doi.org/10.1038/nprot.2015.128.CrossRefPubMedGoogle Scholar
  48. 48.
    Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, et al. Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep 2016;6:25187.  https://doi.org/10.1038/srep25187.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Messner S, Agarkova I, Moritz W, Kelm JM. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 2013;87(1):209–13.  https://doi.org/10.1007/s00204-012-0968-2.CrossRefPubMedGoogle Scholar
  50. 50.
    Nguyen DG, Funk J, Robbins JB, Crogan-Grundy C, Presnell SC, Singer T, et al. Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS ONE 2016;11(7):e0158674.  https://doi.org/10.1371/journal.pone.0158674.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Janssen AW, Betzel B, Stoopen G, Berends FJ, Janssen IM, Peijnenburg AA, et al. The impact of PPARalpha activation on whole genome gene expression in human precision cut liver slices. BMC genomics 2015;16:760.  https://doi.org/10.1186/s12864-015-1969-3.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010;10(1):51–8.  https://doi.org/10.1039/b913221j.CrossRefPubMedGoogle Scholar
  53. 53.
    Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, et al. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 2015;43(7):1091–9.  https://doi.org/10.1124/dmd.115.063495.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Chapman KA, Collado MS, Figler RA, Hoang SA, Armstrong AJ, Cui W, et al. Recapitulation of metabolic defects in a model of propionic acidemia using patient-derived primary hepatocytes. Mol Genet Metab 2016;117(3):355–62.  https://doi.org/10.1016/j.ymgme.2015.12.008.CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  • Abdul M. Oseini
    • 1
  • Banumathi K. Cole
    • 2
  • Danny Issa
    • 1
  • Ryan E. Feaver
    • 2
  • Arun J. Sanyal
    • 1
    • 3
  1. 1.Division of Gastroenterology, Department of MedicineVCU School of MedicineRichmondUSA
  2. 2.HemoShear TherapeuticsCharlottesvilleUSA
  3. 3.Physiology and Molecular PathologyRichmondUSA

Personalised recommendations